Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Costamare Inc Q1 2026 Earnings Call - Secures $2.8B in New Contracts with COSCO While Boosting Dividend
Costamare Inc. delivered a strong first quarter in 2026, posting adjusted net income of $76 million and ending the period with $645 million in liquidity. The shipping company is aggressively expanding...
- Costamare reported Q1 2026 adjusted net income of $76 million ($0.63 per share), demonstrating strong near-term profitability.
- The company secured 16 newbuilding contracts with COSCO Shipping, adding $2.8 billion in incremental contracted revenue over 15 to 8-year charters.
- Total contracted revenues now stand at $6.2 billion, with a TEU-weighted remaining charter duration of 6.1 years, providing exceptional cash flow visibility.
- +7 more takeaways
Amarin Corporation Q1 2026 Earnings Call - Vascepa Prescriptions Surge 17% Amid European Partnership Launch and Cash Flow Turnaround
Amarin Corporation delivered a decisive pivot in Q1 2026, transforming from a cash-burner into a cash-flow-positive entity while accelerating its global commercial strategy. The company reported $45.1...
- U.S. Vascepa-branded prescriptions rose 17% year-over-year in Q1 2026, with the company capturing 48% of the total icosapent ethyl market as generic competition continues to reshape the landscape.
- Total net revenue reached $45.1 million, supported by a 113% quarter-over-quarter increase in European revenue to $4.9 million under the new partnership model with Recordati.
- Amarin achieved its second consecutive quarter of positive operating cash flow, generating $6.4 million in Q1 2026 and ending with a debt-free balance sheet and $308 million in cash.
- +7 more takeaways
Virtu Financial Q1 2026 Earnings Call - Record Trading Income Driven by Capital Expansion and Execution Services Momentum
Virtu Financial delivered a historic first quarter in 2026, posting record Adjusted Net Trading Income of $787 million. The result was not a fluke of favorable volatility but a direct function of a de...
- Record Q1 2026 performance: Adjusted Net Trading Income hit $787 million ($12.9 million per day), an all-time quarterly high for the firm.
- Aggressive capital expansion: Virtu added over $500 million in new trading capital in the last seven months, maintaining a return on total capital exceeding 100%.
- Execution Services momentum: The VES segment reported $2.5 million per day in NT, marking eight consecutive quarters of growth and serving as a key diversification engine.
- +7 more takeaways
Blackbaud Q1 2026 Earnings Call - Agentic AI Launch Drives New Revenue Streams and Margin Expansion
Blackbaud reported a strong start to fiscal 2026 with Q1 organic revenue growth of 4.2% to $281 million and non-GAAP EPS rising 20% to $1.14. The company is betting heavily on its new "Agents for Good...
- Q1 2026 organic revenue grew 4.2% year-over-year to $281 million, reflecting steady demand for mission-critical software in the social impact sector.
- Non-GAAP EPS rose 20% to $1.14, beating expectations and demonstrating the impact of cost management and operational efficiency improvements.
- Free cash flow surged nearly 50% year-over-year to $37 million, providing ample liquidity for continued investment and capital return to shareholders.
- +7 more takeaways
Veralto Corporation Q1 2026 Earnings Call - Raised Guidance on Core Sales Momentum and New Cost Program
Veralto kicked off 2026 with a resilient start, delivering approximately 7% total sales growth and 13% adjusted EPS growth. The company raised its full-year adjusted EPS guidance to $4.20-$4.28, signa...
- Full-year adjusted EPS guidance raised to $4.20-$4.28, up from previous estimates, reflecting strong Q1 performance and accelerating core sales.
- Q1 2026 delivered approximately 7% total sales growth and 13% adjusted EPS growth, underscoring the resilience of Veralto's essential product portfolio.
- Water Quality segment shows mid-single-digit growth in municipal markets and mid-to-high single-digit growth in industrial markets, driven by data centers and semiconductor demand.
- +7 more takeaways
GSK Q1 2026 Earnings Call - Specialty Medicines Surge Shatters Records as HIV Pipeline Accelerates
GSK delivered a robust Q1 2026, with sales climbing 5% to GBP 7.6 billion and core operating profit up 10%. The growth engine is unmistakably Specialty Medicines, which surged 14%, fueled by a record-...
- Specialty Medicines sales jumped 14%, driving overall revenue growth of 5% to GBP 7.6 billion, with core operating profit rising 10%.
- Shingrix posted a record GBP 1 billion in quarterly sales, up 20%, with Europe leading a 51% surge from new immunization programs.
- Nucala’s COPD expansion in the U.S. is gaining traction, with new patient starts up 65% year-over-year and market share approaching 45%.
- +12 more takeaways
Veralto Corporation Q1 2026 Earnings Call - Raised Full-Year EPS Guidance Amid Strong Core Demand
Veralto delivered a robust Q1 2026, posting ~7% core sales growth and 13% adjusted EPS growth, driven by resilient demand in water quality and packaging & industrial solutions. The company raised its ...
- Raised full-year adjusted EPS guidance to $4.20-$4.28 per share, up from prior estimates, reflecting strong Q1 performance and accelerating core sales growth.
- Delivered ~7% core sales growth and 13% adjusted EPS growth in Q1 2026, powered by resilient demand across water quality and packaging & industrial segments.
- Launched a new enterprise-wide cost optimization program, with 50% of run-rate savings expected in 2027 and full impact by 2028, layering on top of existing 30-35% earnings fall-through.
- +7 more takeaways
GSK Q1 2026 Earnings Call - Shingrix Sets Record, Oncology and HIV Pipeline Accelerate
GSK reported a strong Q1 2026 with sales up 5% to over GBP 7.6 billion, driven by a 14% surge in Specialty Medicines and a record-breaking GBP 1 billion quarter for Shingrix. Core operating profit gre...
- Sales grew 5% year-over-year to GBP 7.6 billion, with Specialty Medicines leading the charge at a 14% increase. Core operating profit rose 10%, and EPS climbed 9%, reflecting strong execution and favorable product mix.
- Shingrix delivered a historic quarter, surpassing GBP 1 billion in sales with 20% growth. European uptake in national immunization programs and U.S. inventory stocking from the new pre-filled syringe launch fueled the momentum.
- Nucala’s expansion into COPD is paying off, with U.S. new patient starts up 65% year-over-year. The brand is capturing roughly 45% of the U.S. COPD market, with strong early signals in Europe and China.
- +7 more takeaways
Yum China Q1 2026 Earnings Call - Record Operating Profit and Aggressive Expansion
Yum China delivered a record operating profit in Q1 2026, driven by robust store expansion and disciplined cost management, even as delivery-related rider costs pressured margins. The company opened 6...
- Record operating profit of $447 million, up 6% year-over-year, marking a Q1 milestone despite margin pressures.
- Aggressive store expansion: 636 net new stores opened in Q1, ahead of schedule, with full-year target exceeding 1,900.
- KCOFFEE scaling rapidly: Surpassed 2,600 locations, with sales doubling year-over-year and target raised to 5,000 by end of 2027.
- +7 more takeaways
UMC 1Q 2026 Earnings Call - 22nm Revenue Hits Record High as Management Targets 30% Gross Margin in Q2
UMC reported mixed results for the first quarter of 2026, with revenue rising 5.5% year-over-year to TWD 61.04 billion. Net income surged 50% sequentially to TWD 16.17 billion, driven by non-operating...
- UMC's Q1 2026 revenue reached TWD 61.04 billion, up 5.5% year-over-year but flat sequentially, reflecting modest shipment gains amid a transitional market.
- Net income jumped 50% sequentially to TWD 16.17 billion, primarily driven by a 50% surge in non-operating income from stock market performance rather than core operational leverage.
- Gross margin contracted to 29.2% from 30.7% in Q4 2025, pressured by rising depreciation expenses from the Singapore 12-inch fab ramp and increased energy and logistics costs.
- +9 more takeaways